Led by BioN­Tech, six biotechs line up for Oc­to­ber IPOs

Oc­to­ber: The sea­son of swirling red leaves, Jack-o-lanterns, post­sea­son base­ball and this year, a fresh har­vest of six biotech IPOs ripe with clin­i­cal-stage drugs, try­ing to raise a com­bined $817 mil­lion next week.

All of the com­pa­nies have ear­marked a sub­stan­tial por­tion of the ex­pect­ed pro­ceeds to clin­i­cal work, push­ing such ther­a­pies as mR­NA for melanoma, inebi­lizum­ab for NMOSD, and an­ti­bod­ies for blood can­cer and sol­id tu­mors clos­er to tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER